Jakafi

FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)
Yahoo
FDA
Incyte
Jakafi
breakthrough therapies
graft vs host disease
Flag link:
How Has Incyte’s Jakafi Performed in the US?
How Has Incyte’s Jakafi Performed in the US?
Yahoo/Market Realist
Incyte
Jakafi
Novartis
Flag link:
JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials
JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials
Fierce Biotech
Incyte
Jakafi
solid tumors
JAK inhibitors
Flag link:
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
TheStreet.com
ASCO
CTI BioPharma
myelofibrosis
pacritinib
Jakafi
Incyte
Flag link:
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera
Yahoo/Zacks.com
Incyte
Jakafi
FDA
polycythemia vera
Flag link:
Incyte Building Blockbuster Drug One Disease At A Time
Incyte Building Blockbuster Drug One Disease At A Time
Investors.com
Incyte
Jakafi
myelofibrosis
Flag link:
Geron sells last drug in pipeline to J&J unit
Geron sells last drug in pipeline to J&J unit
Yahoo/Reuters
Geron
JNJ
imetelstat
Jakafi
myelofibrosis
Flag link:
Incyte's Jakafi Unlikely to Benefit Pancreatic Cancer Patients
Incyte's Jakafi Unlikely to Benefit Pancreatic Cancer Patients
TheStreet.com
Incyte
Jakafi
pancreatic cancer
Flag link:
Incyte Gains on Positive Jakafi Data
Incyte Gains on Positive Jakafi Data
Yahoo/Zacks.com
Incyte
Jakafi
polycythemia vera
ASCO
Flag link:
Show me the money: Which drugs made the top 10 list on upfront deals?
Show me the money: Which drugs made the top 10 list on upfront deals?
Fierce Biotech
biotech
GED-0301
Celgene
Nogra Pharma
AbbVie
Reata
Bardoxolone
Abbott Labs
Tradjenta
Eli Lilly
Boehringer Ingelheim
FG-4592
AstraZeneca
FibroGen
Pfizer
Bristol-Myers Squibb
Eliquis
Moderna
Forma Therapeutics
dimebon
Medivation
Jakafi
Novartis
Incyte
Flag link:
Incyte Shows Its Path Towards Growth
Incyte Shows Its Path Towards Growth
Seeking Alpha
Incyte
Jakafi
Flag link:
Incyte Has First-Mover Advantage
Incyte Has First-Mover Advantage
Motley Fool
Incyte
myelofibrosis
Jakafi
Novartis
Flag link:
Myelofibrosis Battle: Novartis Vs. Sanofi
Myelofibrosis Battle: Novartis Vs. Sanofi
Seeking Alpha
Novartis
Sanofi
myelofibrosis
Jakafi
Incyte
SAR302503
Flag link:
This Biotech Has So Many Reasons to Be Liked
This Biotech Has So Many Reasons to Be Liked
Motley Fool
Incyte
JAK inhibitors
Jakafi
myelofibrosis
Flag link:
Pop-Worthy Data, Incyte, but Let's See More
Pop-Worthy Data, Incyte, but Let's See More
Motley Fool
Incyte
Jakafi
pancreatic cancer
Flag link:
Does Incyte Deserve Its New Valuation?
Does Incyte Deserve Its New Valuation?
Motley Fool
Incyte
JAK inhibitors
Jakafi
pancreatic cancer
Flag link:
Incyte pancreatic cancer drug improves survival in mid-stage trial
Incyte pancreatic cancer drug improves survival in mid-stage trial
Reuters
Incyte
pancreatic cancer
Jakafi
Flag link:
Is This Myelofibrosis Drug a Blockbuster?
Is This Myelofibrosis Drug a Blockbuster?
Motley Fool
myelofibrosis
Jakafi
Incyte
Flag link:
Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Yahoo/BusinessWire
Incyte
clinical trials
Jakafi
myelofibrosis
Flag link:
Incyte Jakafi outlook still positive after label revisions, says Oppenheimer
Incyte Jakafi outlook still positive after label revisions, says Oppenheimer
Yahoo/Fly on the Wall
Incyte
Jakafi
Flag link:

Pages